Anthracycline doxorubicin-resistant carbonyl reductase-1 knock out mice

The cancer treatment drug doxorubicin (brand name adriamycin) is very effective against tumors, but causes a serious side effect of heart damage. This toxicity occurs in part because the enzyme carbonyl reductase metabolizes the drug into a cardiotoxic form. We created mice with one non-functional copy of the carbonyl reductase 1 gene. These mice are substantially protected against the heart damage that occurs in normal mice treated with doxorubicin. Description (Set) Proposed Use (Set) The mouse we created can serve as a reference for drug screening of compounds that protect against the cardiotoxicity of adriamycin by inhibiting carbonyl reductase.

Inventor(s): Olson, Lisa Erin

Type of Offer: Licensing



« More Medical Patents

---